McKesson released its 2017 third quarter financial results earlier this week.
In Q3 2016, the company reported $633 million in net income attributable to McKesson. This is a 0.16 decline from the $634 million reported in 2015.
The company also reported its revenue for Q3 was $50.1 billion, a 5 percent increase from the $47.9 billion the company reported a year prior.
"I am pleased with our strong cash flow generation and our ability to deploy capital in meaningful and productive ways, particularly strategic acquisitions and share repurchases," said McKesson Chairman and CEO John Hammergren. "Although we were unfavorably impacted in the third quarter by weaker branded pharmaceutical pricing than anticipated, we are updating our fiscal 2017 outlook to reflect McKesson's lower full-year effective tax rate."